Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: IXHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Incannex Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Incannex Healthcare's regulatory disclosures and financial reporting.
Incannex Healthcare Inc. reported positive results from a Phase 2 clinical trial of its investigational therapy PSX-001 (Psi-GAD) for generalized anxiety disorder. The company disclosed the outcome as an other event and directed readers to a detailed press release for more information, indicating that the trial met encouraging benchmarks for this mental health condition. This update highlights progress in Incannex’s clinical development pipeline, although specific efficacy or safety data are contained in the accompanying press release rather than in this report.
Incannex Healthcare Inc. reported that its board has authorized a $20 million share repurchase program. This means the company now has approval to buy back up to that amount of its own common stock, which can reduce the number of shares held by the public over time if the program is used. The update was shared as an other event, with additional details provided in a related press release referenced in the filing.
Incannex Healthcare Inc. (Nasdaq: IXHL) filed a Form 8-K on 8 Aug 2025 announcing that it has received “positive patient-reported outcomes and compelling Phase 2 efficacy data” for IHL-42X, its drug candidate for obstructive sleep apnoea (OSA). The disclosure is provided via a press release attached as Exhibit 99.1 and incorporated under Item 8.01; no financial statements or other quantitative information accompany the notice. The report, signed by CEO Joel Latham, signals meaningful clinical progress for a core pipeline asset but leaves key metrics—statistical significance, safety profile and regulatory timeline—undisclosed. Investors must consult the referenced press release for comprehensive data and next-step development plans.
Incannex Healthcare (NASDAQ: IXHL), an emerging growth company, announced the appointment of Dr. Douglas B. Kirsch to its Clinical Advisory Board on June 24, 2025, specifically to support its Obstructive Sleep Apnea program.
Key details from the 8-K filing:
- The company is listed on The Nasdaq Stock Market with common stock at $0.0001 par value per share
- Headquartered in Norwest, NSW, Australia
- Joel Latham serves as Chief Executive Officer and President
- The company has elected emerging growth company status
- The appointment represents a strategic expansion of expertise in sleep medicine, potentially strengthening the company's clinical development programs
This strategic addition to the advisory board signals Incannex's continued focus on advancing its sleep apnea therapeutic programs and enhancing its clinical development capabilities.